BioVie

38 articles with BioVie

• BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.

  12/1/2021

  BioVie Inc. entered into a debt facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.

• BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update Thursday, November 11th @ 1:00pm ET

  11/4/2021

  BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced that it will host a key opinion leader webinar on complications of advanced liver cirrhosis and a clinical trial update on the Phase 2b BIV201 study on Thursday, November 11, 2021, at 1:00pm Eastern Time.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• BioVie Announces the Appointment of a New Chief Medical OfficerDr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease

  11/1/2021

  BioVie Inc. announced today the appointment of Joseph M. Palumbo, MD, LFAPA, MACPsych, as the Company’s new Chief Medical Officer.

• BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease

  10/26/2021

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced that the FDA has authorized the company to initiate a Phase 2 study assessing NE3107’s potential pro-motoric impact in Parkinson’s disease patients.

• BioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimer’s Disease

  10/13/2021

  BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader (KOL) webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer’s Disease.

• BioVie to Present at Cantor Virtual Global Healthcare Conference

  9/22/2021

  BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, announced the participation of its management team at the Cantor Virtual Global Healthcare Conference to be held September 27-30, 2021.

• BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit

  9/15/2021

  BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit September 22, 2021.

• BioVie Inc. Announces Closing of Public Offering of Common Stock

  8/11/2021

  BioVie Inc. today announced the closing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of $8.00 per share

• 

  Clinical Catch-Up: August 2-6

  8/9/2021

  It was a busy week for clinical trial announcements. Take a look.

• BioVie Inc. Announces Pricing of Public Offering of Common Stock - Aug 09, 2021

  8/9/2021

  BioVie Inc. announced the pricing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of $8.00 per share, for gross proceeds of $20,000,000, before deducting underwriting discounts, commissions and offering expenses.

• BioVie Inc. Announces Proposed Public Offering of Common Stock

  8/6/2021

  BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced that it intends to offer shares of its common stock in an underwritten public offering.

• BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease

  8/5/2021

  BioVie Inc., a clinical-stage company developing innovative drug candidates for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, announced that the Company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer’s Disease.

• BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

  7/27/2021

  SANTA MONICA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that a poster by Christopher L Reading, PhD, BioVie’s Executive Vice President for Neuroscience Research & Development was presented at the 2021 Alzheimer’s Association International Conference (AAIC). Poster 55458 entitled “Rationale for an anti-inflammatory i

• BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

  7/22/2021

  BioVie Inc. announced today that Poster 55458 entitled “ Rationale for an Anti-inflammatory Insulin Sensitizer in a Phase 3 Alzheimer’s Disease Trial” will be presented at the 2021 Alzheimer’s Association International Conference (AAIC), July 28, 2021.

• Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease ManagementPivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021

  7/16/2021

  BioVie Inc. announced today that an article summarizing the scientific rationale for the Company’s upcoming pivotal Phase 3 Trial of its NE3107 asset in Alzheimer’s disease has been published in the medical journal Neurodegenerative Disease Management .

• Development of BioVie’s NE3107 Asset Featured by the American Diabetes AssociationNE3107 Featured in the ADA’s Thought Leadership Film Series at Annual Scientific Session

  6/29/2021

  BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, announced today that a video documentary detailing the development history of the Company’s newly acquired NE3107 asset will be featured in the American Diabetes Association's Thought Leadership Film Series on ADA TV,

• BioVie Added to Russell Microcap® Index

  6/28/2021

  BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced has been added as a member of the broad-market Russell Microcap Index

• BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®Chairman Terren Peizer discusses BioVie’s late-stage drug pipeline with multiple shots on goal

  6/25/2021

  BioVie Inc. today announced an interview with Terren Peizer, Chairman, that will air on The RedChip Money Report ® on the Bloomberg Network in the U.S. on this coming Saturday, June 26th, at 7 p.m. local time in 73 million homes across the United States.

• BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites

  6/24/2021

  BioVie Inc. today announced that the first patient has been enrolled in the Company’s Phase 2b trial of BIV201 (continuous infusion terlipressin) for the treatment of refractory ascites.